Tomas Ramon Vazquez Rodriguez

Tomas Ramon Vazquez Rodriguez

Auto-generated profile, based on publicly available information

Tomas Ramon Vazquez Rodriguez

Hosp Xeral Calde, Dept Rheumatol, Lugo, Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2009 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
TVTomas R. Vazquez‐Rodriguez
Tomas R. Vazquez‐Rodriguez
MLMaria J. Lopez‐Diaz
Maria J. Lopez‐Diaz
JMJose A. Miranda‐Filloy
Jose A. Miranda‐Filloy
CGCarlos Gonzalez‐Juanatey
Carlos Gonzalez‐Juanatey
JLJavier Llorca
Javier Llorca

1 July 2009 in Medicine
Verified
Journal Article
Closed access
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
TVTomas R. Vazquez-Rodriguez
Tomas R. Vazquez-Rodriguez
IGInes Gómez-Acebo
Ines Gómez-Acebo
RPRobustiano Pego-Reigosa
Robustiano Pego-Reigosa
MLMaria J. Lopez-Diaz
Maria J. Lopez-Diaz
JLJavier Llorca
Javier Llorca
Patients with giant cell arteritis (GCA) generally present with cranial ischemic manifestations that are directly related to vascular involvement. They may also experience strokes in the territory of the carotid or the vertebrobasilar artery. We conducted the current study to assess the frequency and predictors of strokes in general, and of vertebrobasilar stroke in particular, at the time of diagnosis in a series of 287 consecutive patients with biopsy-proven GCA diagnosed over a 27-year period at the single hospital for a well-defined population of northwestern Spain. During the study period, 8 (2.8%) patients had strokes (1 in the carotid and 7 in the vertebrobasilar territory) between the onset of symptoms of the disease and 4 weeks after the onset of corticosteroid therapy. Six of the 7 patients with vertebrobasilar stroke were men. In most cases the vertebrobasilar stroke occurred after the onset of corticosteroid therapy. Smoking history was more common among patients with vertebrobasilar stroke (p = 0.01). Patients with vertebrobasilar stroke more commonly had permanent visual loss due to arteritic involvement of ophthalmic branches derived from the internal carotid (3/7; 42.9%) than the rest of GCA patients (33/280; 11.8%) (p = 0.05). Patients with strokes had higher hemoglobin values (13.2 ± 1.5 g/dL) than patients without (11.7 ± 1.6 g/dL) (p = 0.009). Moreover, only 1 (14.3%) of the 7 patients with vertebrobasilar stroke had anemia compared to 157 (56.1%) of the remaining 280 patients (p = 0.05). The best predictors of stroke were permanent visual loss (odds ratio [OR], 5.42) and arterial hypertension (OR, 5.06). In contrast, women (OR, 0.10) and patients with anemia at the time of disease diagnosis (OR, 0.11) had a significantly reduced risk of suffering strokes. Smoking history was the best positive predictor of vertebrobasilar stroke (OR, 5.22). In contrast, a reduced risk of suffering vertebrobasilar strokes was found in individuals who had anemia at the time of GCA diagnosis (OR, 0.13). Results of the current study show an increased risk of strokes, in the vertebrobasilar territory in particular, at the time of GCA diagnosis. Patients with biopsy-proven GCA and traditional cardiovascular risk factors or permanent visual loss have an increased risk of suffering strokes. Results also suggest a potential protective role of anemia against the development of these cerebrovascular complications. Abbreviations: CI = confidence intervals, CT = computed tomography, ESR = erythrocyte sedimentation rate, GCA = giant cell arteritis, IR = incidence ratio, MRI = magnetic resonance imaging, OR = odds ratio, PMR = polymyalgia rheumatica, RD = risk difference, TIA = transient ischemic attack, VEGF = vascular endothelial growth factor.

1 May 2011 in Medicine
Verified
Journal Article
Closed access
LMLuciana Martinez-Lado
Luciana Martinez-Lado
CCCarolina Calviño-Díaz
Carolina Calviño-Díaz
APAngela Piñeiro
Angela Piñeiro
TDTrinidad Dierssen
Trinidad Dierssen
TVTomas R. Vazquez-Rodriguez
Tomas R. Vazquez-Rodriguez
MGMiguel A. Gonzalez-Gay
Miguel A. Gonzalez-Gay
We conducted the present study to determine the incidence of disease flares (relapses and recurrences) in a series of patients with biopsy-proven giant cell arteritis (GCA). We assessed a series of 174 patients who were diagnosed with biopsy-proven GCA, uniformly treated, and followed at the rheumatology division of Hospital Xeral-Calde (Lugo, Spain), the single rheumatology division for a well-defined population. All of them were followed for at least 1 year after the disease diagnosis. Seventy-one (40.8%) experienced relapses or recurrences of the disease. Patients who had relapses or recurrences did not show clinical differences when compared with the remaining biopsy-proven GCA patients. However, the total duration of corticosteroid therapy was significantly longer in those patients who had relapses or recurrences of the disease. The median dose of prednisone and the median duration of corticosteroid treatment at the time of the first relapse were 5 mg/d and 16 months, respectively. Headache (52%) was the most common feature at the time of the first relapse. Polymyalgia rheumatica manifestations occurred in 30% of the patients at that time. However, none of them developed visual loss. Thirty-two patients experienced recurrences of the disease when prednisone dose had been discontinued. The median time from the disease diagnosis to the time of the recurrence was 23 months. The presence of anemia (hemoglobin <12 g/dL) at the time of disease diagnosis was the best predictor of relapses or recurrences of GCA (odds ratio, 2.17; 95% confidence interval, 1.02-4.62; p = 0.04). The results from the present study confirm that relapses and recurrences are frequent in homogenously treated patients with biopsy-proven GCA. A chronic inflammatory response manifested by anemia at the time of disease diagnosis may predict the development of disease flares.

1 November 2009 in Medicine
Verified
Journal Article
Closed access
CGCarlos Gonzalez-Juanatey
Carlos Gonzalez-Juanatey
TVTomas R. Vazquez-Rodriguez
Tomas R. Vazquez-Rodriguez
JMJose A. Miranda-Filloy
Jose A. Miranda-Filloy
TDTrinidad Dierssen
Trinidad Dierssen
IVInes Vaqueiro
Ines Vaqueiro
MGMiguel A. Gonzalez-Gay
Miguel A. Gonzalez-Gay
We conducted the present study to determine whether subclinical macrovascular atherosclerotic disease was present in patients with ankylosing spondylitis (AS) without clinical history of cardiovascular disease. We also sought to establish whether demographic or clinical features of the disease may influence the development of subclinical atherosclerotic disease in a series of patients with AS seen at a community hospital. We recruited 64 patients who fulfilled the modified New York diagnostic criteria for AS from Hospital Xeral-Calde, Lugo, Spain. We excluded patients seen during the recruitment period who had cardiovascular disease or renal insufficiency. We also studied 64 matched controls. Carotid artery intima-media thickness (IMT) and carotid plaques were measured in the right common carotid artery. The study was performed using high-resolution B-mode ultrasound.Patients with AS exhibited greater carotid IMT than did matched controls (mean +/- SD, 0.74 +/- 0.21 mm vs. 0.67 +/- 0.14 mm; p = 0.01; differences of means, 0.077; 95% confidence interval, 0.016-0.139). Carotid plaques were more commonly observed in patients with AS than in controls (19 [29.7%] vs. 6 [9.4%], respectively; p = 0.03). The best predictors for carotid plaques in patients with AS were erythrocyte sedimentation rate (ESR) at time of disease diagnosis (odds ratio [OR], 1.18; 95% confidence intervals [CI], 1.04-1.33; p = 0.01) and duration of disease (OR, 1.39; 95% CI, 1.01-1.92; p = 0.05). In contrast, there was no significant correlation between carotid IMT and either ESR or C-reactive protein in this study. Results of the present study show that patients with AS without clinically evident cardiovascular disease have a high prevalence of subclinical macrovascular disease in the form of increased carotid IMT and carotid plaques compared to matched controls.

13 April 2010 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
CGCarlos Gonzalez‐Juanatey
Carlos Gonzalez‐Juanatey
TVTomas R. Vazquez‐Rodriguez
Tomas R. Vazquez‐Rodriguez
JMJose A. Miranda‐Filloy
Jose A. Miranda‐Filloy
JLJavier Llorca
Javier Llorca

1 September 2008 in Medicine
Verified
Journal Article
Closed access
MAMaria C. Arias-Nuñez
Maria C. Arias-Nuñez
JLJavier Llorca
Javier Llorca
TVTomas R. Vazquez-Rodriguez
Tomas R. Vazquez-Rodriguez
IGInes Gómez-Acebo
Ines Gómez-Acebo
JMJose A. Miranda-Filloy
Jose A. Miranda-Filloy
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
To investigate the epidemiology of systemic sclerosis (SSc) in southern Europe, we assessed the incidence, prevalence, clinical spectrum, and survival of patients diagnosed with SSc in the Lugo region of northwestern Spain. Between January 1988 and December 2006, SSc was diagnosed in 78 Lugo residents according to the criteria proposed by LeRoy and Medsger and/or the 1980 American College of Rheumatology (ACR) preliminary criteria for the classification of SSc. However, only 44 (56.4%) of the 78 patients fulfilled the 1980 ACR criteria for the classification of SSc. The mean age at the time of disease diagnosis was 59.8 ± 13.3 years. Twenty-three (29.5%) met definitions for diffuse SSc (dSSc), and 55 (70.5%) for limited SSc (lSSc). Patients with lSSc had a longer disease duration before the diagnosis (10.2 ± 12.0 yr) than those with dSSc (3.7 ± 3.2yr) (p < 0.001). Based on the criteria proposed by LeRoy and Medsger and/or the 1980 ACR criteria for the classification of SSc, the overall age- and sex-adjusted annual incidence rate over the 19-year study period was 2.3 (95% confidence interval [CI], 1.6-2.5) per 100,000 population aged 15 yr and older (women: 3.5 [95% CI, 2.3-3.9]; men: 1.0 [95% CI, 0.5-1.4]; p < 0.001). Using only the 1980 ACR criteria for SSc, the total annual-adjusted incidence rate was 1.2 (95% CI, 0.9-1.6) per 100,000 population aged 15 years and older (women: 1.8 [95% CI, 1.2-2.5]; men: 0.7 [95% CI, 0.3-1.2]; p < 0.001). The incidence increased significantly in individuals aged 45 years or older. The overall incidence rates of SSc increased over the length of the study (p for trend in the total incidence < 0.001). This was mainly due to a progressive increase of SSc in women between 1993 and 2002. By December 31, 2006, the overall age-adjusted SSc prevalence in the Lugo region of patients who met the criteria proposed by LeRoy and Medsger and/or the 1980 ACR criteria was 27.7 (95% CI, 21.1-35.84) per 100,000 population aged 15 years and older. Cardiopulmonary complications were the leading cause of death (13 of 20 cases). Compared with that in the general population, the probability of survival in patients with SSc was significantly reduced (p < 0.001). The current study establishes a baseline estimate of the incidence and clinical spectrum of SSc in northwestern Spain. According to our results, the incidence and prevalence of SSc in northwestern Spain are similar to those found in Greece and some regions of the United States. Our data confirm a reduced probability of survival in patients with SSc. Abbreviations: ACR = American College of Rheumatology, ANA = antinuclear antibodies, CI = confidence intervals, dSSc = diffuse systemic sclerosis, IIF = indirect immunofluorescence, lSSc = limited systemic sclerosis, lcSSc = limited cutaneous scleroderma, NDI = National Death Index, RP = Raynaud phenomenon, SD = standard deviation, SSc = systemic sclerosis.